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A BS TR AC T
Background
Neurogenin-3 (NEUROG3) is expressed in endocrine progenitor cells and is required 
for endocrine-cell development in the pancreas and intestine. The NEUROG3 gene 
(NEUROG3) is therefore a candidate for the cause of a newly discovered autosomal 
recessive disorder characterized by generalized malabsorption and a paucity of en-
teroendocrine cells.
Methods
We screened genomic DNA from three unrelated patients with sparse enteroendo-
crine cells for mutations of NEUROG3. We then tested the ability of the observed 
mutations to alter NEUROG3 function, using in vitro and in vivo assays.
Results
The patients had few intestinal enteroendocrine cells positive for chromogranin A, 
but they had normal numbers of Paneth’s, goblet, and absorptive cells. We identified 
two homozygous mutations in NEUROG3, both of which rendered the NEUROG3 pro-
tein unable to activate NEUROD1, a downstream target of NEUROG3, and compromised 
the ability of NEUROG3 to bind to an E-box element in the NEUROD1 promoter. The 
injection of wild-type but not mutant NEUROG3 messenger RNA into xenopus em-
bryos induced NEUROD1 expression. 
Conclusions
A newly discovered disorder characterized by malabsorptive diarrhea and a lack of 
intestinal enteroendocrine cells is caused by loss-of-function mutations in NEUROG3.
The New England Journal of Medicine 
Downloaded from nejm.org at BRONX PSYCHIATRIC CENTER on August 22, 2019. For personal use only. No other uses without permission. 
 Copyright © 2006 Massachusetts Medical Society. All rights reserved. 
neurog3 mutations and malabsorptive diarrhea
n engl j med 355;3 www.nejm.org july 20, 2006 271
P atients with congenital diarrhea generally present within the first weeks after birth with severe, life-threatening wa-
tery diarrhea that can be classified as either secre-
tory or malabsorptive in nature.1 Routine clinical 
evaluation, including intestinal biopsy, may be 
used to further categorize the diarrhea according 
to the severity of the inflammation and to as-
sess the integrity of the crypt–villus axis and the 
architecture of the epithelial layer. On the basis 
of both clinical and pathological characteris-
tics, various specialized formulas may be used 
to minimize the diarrheal symptoms, although 
some children require extended periods of intra-
venous nutrition to sustain normal growth and 
development.
Many patients with congenital diarrhea in 
early infancy have a selective defect in one of a 
variety of transporters and enzymes that have 
nonredundant roles in the processes of nutrient 
assimilation and ion absorption.2 In contrast, 
generalized malabsorptive disorders involving 
simple nutrients (such as monosaccharides and 
amino acids) result from a nonselective decline 
in the capacity to absorb nutrients, which is due 
to either a decrease in the small-bowel surface 
area or mucosal inflammation.1 Thus far, defects 
in the structure and function of absorptive and 
inflammatory cells of the gut have been associ-
ated with diarrhea and the alteration of ion and 
nutrient absorption and secretion.
Studies involving mice have shown that two 
basic helix–loop–helix transcription factors — 
mouse atonal homologue 1 (encoded by Math1) 
and Neurogenin-3 (Neurog3, encoded by Neurog3) 
— influence the fates of enteroendocrine, Pan-
eth’s, goblet, and enterocyte cells.3-6 Neurog3−/− 
mice lack endocrine cells in the pancreas and in-
testine, which is presumably why they die of dia-
betes during the first several days of life.3 These 
and other findings suggest that Neurog3 is a key 
transcription factor that controls the fate of en-
docrine cells in both the pancreas and intes-
tine.3-6 Despite its clear role in the development 
of endocrine cells, no disease-causing mutation 
of NEUROG3 (or of the genes encoding the closely 
related NEUROG1 and NEUROG2) has to our 
knowledge been described in humans.7 We stud-
ied three boys with severe generalized congenital 
malabsorptive diarrhea to determine the clinical 
characteristics and molecular basis of this disor-
der in humans. 
Me thods
Patients
We identified three boys with similar clinical char-
acteristics and obtained informed, written consent 
from the legal guardians of each patient. The study 
protocol was approved by the institutional review 
board of the University of California at Los Ange-
les. Pertinent medical and pathology records were 
obtained and summarized for each patient.
Pathological Analysis of the Intestine
We analyzed formalin-fixed, paraffin-embedded 
biopsy samples of intestinal tissue using immu-
nohistochemical techniques and stained them 
with hematoxylin and eosin and periodic acid–
Schiff. We carried out immunohistochemical as-
says for chromogranin A (Dako), synaptophysin 
(Dako), lysozyme (Dako), serotonin (Zymed), gas-
trin (Dako), somatostatin (Dako), and vasoactive 
intestinal polypeptide (Biogenics) with standard 
techniques and using commercially available an-
tibodies, according to the manufacturers’ instruc-
tions. Archival samples of small bowel were used 
as control samples. Electron microscopy was used 
to examine biopsy samples of the small-intestinal 
mucosa from each patient. Information on DNA 
sequencing, cloning, site-directed mutagenesis, 
messenger RNA (mRNA) and protein synthesis, 
and analysis in xenopus embryos can be found in 
the Supplementary Appendix, available with the 
full text of this article at www.nejm.org.
R esult s
Overview of Clinical Histories
The patients presented during the first several 
weeks of life with vomiting, diarrhea, dehydration, 
and a severe hyperchloremic metabolic acidosis 
after the ingestion of standard cow’s-milk–based 
formula (Table 1 and the Supplementary Appen-
dix). They were readmitted on several occasions 
during the first month of life when it became 
clear that they all had chronic unremitting diar-
rhea that was malabsorptive in nature. Compre-
hensive evaluations for allergic, immunologic, in-
fectious, and metabolic causes of diarrhea were 
all negative. The pancreatic exocrine function was 
normal in all three patients. The radiographic eval-
uation of Patients 1 and 2 showed that the length 
and orientation of the small bowel were normal. 
Biopsy of the stomach and esophagus revealed 
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normal histologic features and biopsy of the duo-
denum and sigmoid colon revealed histologic fea-
tures initially interpreted as normal. The activity 
of various mucosal disaccharidases was within 
the normal range.
The volume of diarrhea in all three patients 
was in the range of 60 to 120 ml per kilogram of 
body weight per day (normal stool volume, less 
than 20). The diarrhea ceased during periods of 
fasting. Water was well tolerated, but the admin-
istration of a glucose-based oral rehydration so-
lution led to diarrhea. Two patients continued to 
have diarrhea while being fed a carbohydrate-free 
cow’s-milk–based formula, and the addition of 
either fructose or glucose exacerbated the sever-
ity of the diarrhea. Several amino acid–based for-
mulas, including one without carbohydrates, were 
administered but did not lead to resolution of 
the diarrheal symptoms in two patients. Patient 1 
even had diarrhea when long- or medium-chain 
triglycerides or amino acids (typically used for 
parenteral nutrition) were added to the drinking 
water.
All three children were eventually discharged 
home with the means of delivering and receiving 
parenteral nutrition and limited enteral feeding 
and were readmitted on several occasions because 
of sepsis related to an infection from the central 
venous catheter. Parenteral nutrition was discon-
tinued in the third patient because of the severity 
and frequency of such sepsis. Severe cholestatic 
liver disease and portal hypertension developed 
in the index patient (Patient 1), and by two years 
of age the patient underwent a native subtotal en-
terectomy and total hepatectomy and received an 
orthotopic en bloc liver–intestine transplant. He 
Table 1. Baseline Characteristics of the Patients.*
Characteristic Patient 1 Patient 2 Patient 3
Age 35 mo 8 yr 9 yr
Sex M M M
Birth weight — g 2530 2720 2334
Hyperchloremic metabolic acidosis Yes Yes Yes
Cessation of diarrhea while receiving noth-
ing by mouth
Yes Yes Yes
Viral, parasitic, and bacterial pathogens None None None
Sweat chloride test and test for CF DNA Normal Normal Normal (CF DNA ND)
Mitochondrial DNA Normal Normal ND
Lactate and pyruvate Normal Normal ND
Serum amino acids Normal Normal Normal
Urine organic acids Normal Normal Normal
Cholesterol and triglyceride panel Normal Normal Normal
Apolipoprotein profile Normal Normal ND
Zinc, ammonia, and creatine kinase Normal Normal ND
HIV-1 or HIV-2 antibody Negative Negative Negative
T-cell and B-cell subgroups Normal Normal Normal
Stool
Trypsin activity Maximum (+4) ND ND
Reducing substances Maximum (+2) Maximum (+2) Maximum (+2)
Alpha-1-antitrypsin activity Normal Mild elevation ND
Mucosal lactase, sucrase, and maltase 
activity 
Normal Normal Normal
Upper gastrointestinal and small-bowel 
follow-through 
Normal Normal ND
Secretin stimulation test (pancreatic 
enzymes)
ND Normal Normal
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did well, without diarrhea and while being fed 
enterally, for nearly a year but then died unexpect-
edly of sepsis. The second patient continued to 
receive parenteral nutrition at home until the age 
of two years, and since then, he has been receiv-
ing supplemental oral vitamins and electrolytes. 
Patients 2 and 3 continue to have large-volume 
loose stools daily, and their weights are either at 
or below the 5th percentile for age. Type 1 dia-
betes developed in both patients when they were 
8 years old.
Histopathological Analysis of the Intestine
We obtained small-bowel–biopsy samples from 
the index patient at various ages; these samples 
consistently revealed a normal villus structure and 
no pathologic infiltration of inflammatory cells 
(Fig. 1). Extensive evaluation of the small- and 
large-bowel mucosa after enterectomy showed 
profound dysgenesis of the enteroendocrine cells 
(compare Fig. 1D with Fig. 1E). The appearance 
of the remaining mucosa, including the Paneth’s 
and goblet cells, was normal (Fig. 1A, 1B, and 1C). 
Staining for chromogranin A revealed only one 
enteroendocrine cell (which was aberrant in shape) 
in the more than 350 small-bowel crypts examined 
(Fig. 1D) and none in the colon. In contrast, five 
or six enteroendocrine cells were present per crypt 
in normal mucosa (Fig. 1E). The lack of cells was 
also observed in biopsy specimens obtained from 
the index patient 18 months before enterectomy. 
Staining of small-bowel–biopsy samples for chro-
mogranin A also revealed a dramatic depletion 
of enteroendocrine cells in Patients 2 and 3. Only 
Table 1. (Continued.)
Characteristic Patient 1 Patient 2 Patient 3
Response to various nutrients†
Water Normal Normal Normal
Water + MCT Diarrhea ND ND
Water + LCT Diarrhea ND ND
Water + amino acids Diarrhea ND ND
Glucose-based oral rehydration solution Diarrhea Diarrhea Diarrhea
Carbohydrate-free formula Diarrhea Diarrhea ? Decreased
Carbohydrate-free formula + fructose Diarrhea Diarrhea ? Decreased
Carbohydrate-free formula + glucose Diarrhea Diarrhea Diarrhea
Amino acid–based formulas Diarrhea Diarrhea Diarrhea
Carbohydrate-free, amino acid–based 
formula 
Diarrhea ND ND
Cow’s-milk–based formula Diarrhea Diarrhea Diarrhea
Soy-protein–based formula Diarrhea Diarrhea Diarrhea
Response to drug management (during re-
ceipt of cow’s-milk–based formula)
Pancreatic enzymes Diarrhea Diarrhea Diarrhea
Loperamide Diarrhea Diarrhea ND
Cholestyramine Diarrhea Diarrhea Diarrhea
Clinical course
Received home PN (duration) Yes (24 mo) Yes (23 mo) Yes (2 mo)
Currently receiving PN No‡ No No
Current diarrhea No‡ Yes Yes
Small-bowel transplantation Yes No No
* CF denotes cystic fibrosis, ND not done, HIV human immunodeficiency virus, MCT medium-chain triglycerides, 
LCT long-chain triglycerides, and PN parenteral nutrition.
† Diarrhea is defined as diarrhea with a volume of more than 20 ml per kilogram of body weight per day.
‡ Patient died of sepsis when manuscript was under review.
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1 cell was identified in 100 crypts in the duode-
num, and 8 were identified in 100 crypts in the 
jejunum.
The lack of the general endocrine marker syn-
aptophysin also indicated an extreme deficiency 
of endocrine cells in the three patients. Only 1 cell 
in 350 crypts was positive for serotonin. No cells 
containing gastrin or somatostatin were identified 
in more than 300 crypts, and as expected, vaso-
active intestinal polypeptide stained only nerves 
(data not shown). The results of electron micros-
copy indicated that the patients had normal brush 
borders, microvilli, intracellular mitochondria, and 
tight junctions. We observed an occasional lipid-
laden enterocyte in the upper third of the villus, 
an abnormal finding previously described in pa-
tients with abetalipoproteinemia and hypopro-
teinemia.1
Sequencing of NEUROG3
We hypothesized that the enteroendocrine-cell dys-
genesis was caused by a null mutation of NEUROG3. 
We therefore sequenced NEUROG3 in DNA from 
blood samples from the index patient and observed 
a homozygous missense change predicted to re-
sult in the substitution of a serine residue for an 
arginine residue at position 107 (R107S) (Fig. 2). 
The other two patients had a homozygous mis-
sense change predicted to result in the substitu-
tion of a leucine residue for an arginine residue at 
position 93 (R93L) (Fig. 2). Position 107 is in the 
first helix of the protein, which is critical to the 
activation of downstream genes. Position 93 is in 
the DNA-binding or basic domain (i.e., the region 
that binds the promoters of genes regulated by 
NEUROG3), just upstream of the first helix (Fig. 
2B). We did not observe these mutations in spec-
imens from 100 ethnically matched control per-
sons (data not shown). The arginine residues at 
positions 93 and 107 are conserved in all known 
neurogenin proteins across a wide range of spe-
cies, including Caenorhabditis elegans (Fig. 2B). We 
hypothesize that the missense mutations result in 
loss of function of the protein because of their 
critical location and the extent to which the af-
fected residues are conserved across species.
A B C
ED
Figure 1. Sample of Small Bowel with Sparse Enteroendocrine Cells from Patient 1.
The crypt and villus architecture was normal (hematoxylin and eosin, Panel A), as were goblet cells (periodic acid–
Schiff, Panel B) and Paneth’s cells (antilysozyme, Panel C), but there was a deficiency of enteroendocrine cells (anti-
chromogranin, Panel D), as compared with the number in a control sample (antichromogranin, Panel E).
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Gallus gallus
G. gallus
Danio rerio
D. rerio
D. rerio
Cynops pyrrhogaster
Xenopus laevis   
X. laevis
Basic Helix II
21482 95 138 190
RPKSELALSKQRRSRRKKANDRERNRMHNLNSALDALRGVLPTFPDDAKL 119
GAKTAETVQRIKKTRRLKANNRERNRMHNLNAALDALREVLPTFPEDAKL 148
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RPKSELALSKQRRSRRKKANDRERNRMHNLNSALDALRGVLPTFPDDAKL 119 
GAKTAETVQRIKKTRRLKANNRERNRMHNLNAALDALREVLPTFPEDAKL 148
RVRSEALLHSLRRSRRVKANDRERNRMHNLNAALDALRSVLPSFPDDTKL 129 
RVRSEALLHSLRRSRRVKANDRERNRMHNLNAALDALRSVLPSFPDDTKL 129
RVRSEALLHSLRRSRRVKANDRERNRMHNLNAALDALRSVLPSFPDDTKL 129
RPKSELALSKQRRSRRKKANDRERNRMHNLNSALDALRGVLPTFPDDAKL 119
AARTAETAQRIKRSRRLKANNRERNRMHNLNAALDALRDVLPTFPEDAKL 114
RARTEALLHTLKRSRRVKANDRERNRMHHLNAALDELRSVLPTFPDDTKL  78
KLKKLMSTSRQRGNRRVKANDRGRHRMHNLNSALDNLRSVLPTFPDDAKL 114 
RARNETTVHVVKKNRRLKANDRERNRMHNLNDALDALRSVLPAFPDDTKL 106 
RARNETTVHVVKKNRRLKANDRERNRMHNLNDALDALRSVLPAFPDDTKL 106
RVKSEAIQHSIKKNRRVKANDRERNRMHSLNYALDKLRCILPSFPDDTKL 114
--GKSGETVLKIKKTRRVKANNRERNRMHNLNSALDSLREVLPSLPEDAKL 117
RKRSPATIERAKTVRRDKANARERRRMNSLNDALEHLRGILPALPDEPKM  98
----GDTVLKIKKTRRVKANNRERNRMHHLNYALDSLREVLPSLPEDAKL 121 
1
3
2
1
3
2
1
3
1
3
2
1
3
2
Unknown
Unknown
1a
1b
A
B
Species Neurogenin
Figure 2. Sequence of NEUROG3 (Panel A) and Structure of the Protein (Panel B).
Panel A shows the NEUROG3 sequence in Patient 1 (top) and in Patients 2 and 3 (bottom). The human NEUROG3 
gene (region encoding amino acids 93 to 108) is shown, and the specific mutations are indicated by the arrows. Patient 1 
had a homozygous mutation resulting in the substitution of serine for arginine in residue 107 (R107S), whereas Pa-
tients 2 and 3 had a homozygous mutation resulting in the substitution of leucine for arginine in residue 93 (R93L). 
Panel B shows the structure of NEUROG3, including the basic helix–loop–helix (bHLH) domain. The conservation 
of various residues within this domain is shown for all members of the neurogenin family in a wide variety of spe-
cies. Unknown means that the specific type of neurogenin is unknown. Dashes represent amino acids unrelated to 
the neurogenin family. The numbers to the right of the sequences are the residue numbers for the last amino acid 
listed for each species.
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Transactivation of the NEUROD1 Promoter
When bound to another transcription factor, 
E47, NEUROG3 activates the transcription of the 
NEUROD1 gene.8 More specifically, the NEUROG3–
E47 heterodimer binds two well-characterized 
E-box DNA elements (called E-box 1 and E-box 3) 
that lie in the promoter region of NEUROD1; such 
binding is critical to the activation of NEUROD1 
by the heterodimer.8 A reporter vector composed 
of the three E-boxes in the promoter region of 
NEUROD1 followed by the luciferase gene was co-
transfected, together with a wild-type NEUROG3 
expression vector, into HeLa cells. The resulting 
promoter activity was five times that of the nega-
tive control (Fig. 3A). We observed insignificant 
promoter activity, however, when we replaced the 
wild-type NEUROG3 expression vector with a vec-
tor encoding either the R93L or R107S NEUROG3 
mutant. A Western blot of transfected, flag-tagged 
NEUROG3 revealed approximately equal amounts 
of the wild-type and mutant forms (Fig. 3B). We 
therefore concluded that the mutations render 
NEUROG3 incapable of inducing NEUROD1 gene 
expression in this transient-transfection assay.
Interaction between NEUROG3 
and the NEUROD1 Promoter
To clarify the mechanism by which the muta-
tions of NEUROG3 prevented the activation of the 
NEUROD1 promoter, we assessed the ability of each 
mutant protein to interact in vitro with an E-box 
in the NEUROD1 promoter. The E47 homodimer 
bound to the E-box 1 DNA element in a specific 
manner (lane 2 in Fig. 3C). Wild-type NEUROG3, 
on the other hand, failed to bind DNA in the ab-
sence of E47 (data not shown), but the NEUROG3–
E47 heterodimer formed an abundant and spe-
cific complex, indicating robust binding between 
the heterodimer and the DNA element (lanes 3, 4, 
and 5 in Fig. 3C). In contrast, mutant NEUROG3 
(encoded by constructs containing the R93L or 
R107S mutation) generated less signal than the 
wild-type NEUROG3, indicating weaker binding 
(lanes 6 through 11 in Fig. 3C). Approximately 
equal amounts of E47 and NEUROG3 (both wild-
type and mutant forms) were used in this analy-
sis (Fig. 3D). These data suggest that the failure 
of mutant NEUROG3 to augment the NEUROD1 
promoter activity is due, at least in part, to its com-
promised ability to bind the NEUROD1 promoter.
In Vivo Activation of NEUROD1
The ectopic injection of NEUROG3 RNA into xeno-
pus embryos induces the expression of NeuroD1 
in neurons.8 We therefore tested the ability of mu-
tant NEUROG3 to transactivate NeuroD1 produc-
tion in vivo by injecting mouse Neurog3 mRNA 
(wild-type or mutant) into xenopus embryos and 
then evaluating NeuroD1 levels (Fig. 4). The human 
and mouse orthologues of the protein showed 
a high degree of similarity (72 percent overall 
and 98 percent in the critical helix–loop–helix 
DNA-binding domain), and we were unable to 
detect significant differences in the extent to which 
they activated NEUROD1. Wild-type Neurog3 mRNA 
induced ectopic NeuroD1-positive neurons in the 
injection side of the embryo (Fig. 4B). We observed 
Figure 3 (facing page). In Vitro Effects of NEUROG3 
on the NeuroD1 Promoter.
The clone containing the NeuroD1 promoter (NeuroD1-3E) 
was cotransfected into HeLa cells with either wild-type 
or mutant (R107S or R93L) NEUROG3 expression vec-
tors. Panel A shows the resulting activity of firefly lucif-
erase per unit of renilla luciferase, relative to that of the 
negative control: NeuroD1-3E cotransfected with the 
expression vector containing the mutant NEUROG3 
(R93L) cloned in the antisense orientation. The TATA 
vector is the proximal promoter region of NeuroD1 that 
lacks the E-boxes. Values are means ±SE of six replicates 
from three different experiments. Panel B shows the re-
sults of Western blotting, with anti-flag M2 and anti–
β-actin antibodies, of the whole-cell lysate from HeLa 
cells into which flag-tagged wild-type and mutant 
NEUROG3 vectors had been transiently transfected 
24 hours earlier. “None” represents cells into which 
NEUROG3 was not introduced. β-Actin served as an 
internal control for the equal loading of protein. Panel 
C shows the binding of a NeuroD1 promoter element 
to NEUROG3–E47. An electrophoretic mobility shift 
assay was performed with the use of a recombinant 
protein (E47 or NEUROG3–E47) and a labeled duplex 
oligonucleotide (NeuroD1 E-box 1). Recombinant E47 
alone (lane 2), with wild-type NEUROG3 (lanes 3, 4, 
and 5), or with mutant NEUROG3 — R107S (lanes 6, 
7, and 8) or R93L (lanes 9, 10, and 11) — bound to the 
oligonucleotide duplexes. The formation of complexes 
with the labeled oligonucleotide duplexes lessened 
proportionally in the presence of 10 and 100 times the 
baseline amount of unlabeled oligonucleotide duplexes 
(increasing levels indicated by the increasing slope of 
the black triangles). Panel D shows the results of the in 
vitro translation of E47 and NEUROG3 (wild-type and 
mutant forms) labeled with [35S]methionine and visual-
ized on a 12 percent acrylamide gel to confirm their 
relative sizes and abundances.
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no such neurons in the sham-injected control or 
in the side that was not injected (Fig. 4A) and very 
few, if any, in the embryos injected with either of 
the two mutant forms of mRNA (Fig. 4D and 4F). 
These results suggest that the mutations attenu-
ate NEUROG3 function in vivo.
Discussion
Our findings indicate that disruption of the path-
way that determines the differentiation of intes-
tinal absorptive cells (enterocytes) and secretory 
cells (enteroendocrine, Paneth’s and goblet cells) 
has profound effects on the capacity of the small 
intestine to absorb nutrients. Specifically, the clin-
ical findings highlight a critical role of enteroen-
docrine cells in augmenting nutrient absorption. 
We have named the disorder exemplified by these 
cases “enteric anendocrinosis.”
The fate of the embryonic or adult stem cell 
is determined by a series of molecular switches. 
The first switch is the lateral inhibition by a ligand 
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of the Notch receptor.9,10 In the cells that express 
it, the ligand triggers a signaling cascade domi-
nated by the sequential expression of numerous 
basic helix–loop–helix transcription factors, such 
as MATH1.5,11,12 Cells expressing the Notch recep-
tor, on the other hand, are induced (through the 
binding of the Notch receptor by one of its ligands) 
to inhibit this cascade of basic helix–loop–helix 
transcription factors — resulting in the exclusive 
development of absorptive cells.9,11-13 This inhi-
bition is mediated by a molecule called Hairy and 
Enhancer of Split (HES1): its expression is in-
duced through the activation of the Notch recep-
tor, and it inhibits the cascade of basic helix–
loop–helix transcription factors by preventing the 
expression of MATH1. 
The intestines of Math1−/− mice lack secretory 
cells, and the mice inexplicably die soon after 
birth. Neurog3 expression is abrogated in Math1-
null mice, suggesting that Neurog3 is a downstream 
target of Math1. Unlike their Math1-null counter-
parts, Neurog3-null mice have normal goblet and 
Paneth’s cells and no islet cells in the pancreas, 
and like Math1−/− mice, they lack enteroendocrine 
cells.3-6 Diarrhea has not been described in either 
strain of mouse. Although diabetes has been sug-
gested as the cause of death of Neurog3-null mice, 
Math1-null mice presumably have normal pancre-
atic function, because Math1 is not expressed in 
the pancreas.5 Combining the data from mouse 
knockout studies and our findings, it appears that 
loss-of-function mutations of NEUROG3 contribute 
to early death by causing a severe malabsorptive 
diarrhea.
The particular hormone factors and paracrine 
factors downstream of NEUROG3 that affect nu-
trient absorption have yet to be identified.14 They 
may lie downstream of transcription factors ac-
tivated by Neurog3: NeuroD1, Pdx1, or both.15,16 
Mice deficient in either NeuroD1 or Pdx1 lack a 
subgroup of enteroendocrine cells, but because 
they die shortly before or after birth, the relevance 
of a deficiency of a portion of enteroendocrine 
cells to early death is uncertain, and diarrhea has 
not been described in these mice. An assortment 
of null mice, with selective deficiencies of specific 
hormones secreted by the enteroendocrine cells, 
have been created.14-18 Many of these mice have 
specific physiological phenotypes, but none have 
been described as having the malabsorption, mal-
nutrition, or perinatal death that would mimic the 
clinical findings in our patients.
Two other findings, together with our results, 
indicate that enteroendocrine cells and their prod-
ucts have a profound role in the capacity of the 
small intestine to absorb simple nutrients. First, 
the transient depletion of enteroendocrine cells 
was reported in a patient with temporary malab-
sorption and the autoimmune polyglandular syn-
drome type I; the symptoms resolved after the 
spontaneous recovery of enteroendocrine cells.19 
Second, a mutation of the gene encoding the en-
zyme prohormone convertase 1 has been reported 
to result in malabsorption, obesity, hypoadrenal-
ism, and elevated levels of prohormones with a 
proportionate depletion of mature hormones.20 
This family of enzymes is located in enteroendo-
crine and other endocrine cells and converts inac-
tive peptide hormone precursors into their mature 
functional forms.20,21
A
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Not Injected D
B Injected, Wild-type Neurog3
Injected, Mutant Neurog3 (R107S)
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500 μm
Figure 4. In Vivo Activation of NeuroD1 by NEUROG3.
Panel A shows the normal expression of NeuroD1 in the eye, trigeminal 
ganglia (TG), and dorsal-root ganglia (DRG) of a Xenopus laevis embryo. 
Shown are the side of each embryo that was injected (Panels B, D, and F) 
and not injected (Panels A, C, and E) with wild-type mouse Neurog3 (Pan-
els A and B) or mutant mouse Neurog3 — R107S (Panels C and D) or R93L 
(Panels E and F). Some areas are magnified (insets), and some ectopic 
NeuroD1-positive neurons are marked by arrow (Panel B). 
The New England Journal of Medicine 
Downloaded from nejm.org at BRONX PSYCHIATRIC CENTER on August 22, 2019. For personal use only. No other uses without permission. 
 Copyright © 2006 Massachusetts Medical Society. All rights reserved. 
neurog3 mutations and malabsorptive diarrhea
n engl j med 355;3 www.nejm.org july 20, 2006 279
How does an absence of enteroendocrine cells 
lead to malabsorptive diarrhea? Sensors that prime 
the intestine for the absorption of luminal nutri-
ents have long been suggested to play a critical 
role in intestinal adaptation.22 However, their pre-
cise identity, location, and function have remained 
elusive. Various nutrient, pH, and osmotic sensors 
are present in enteroendocrine cells and submu-
cosal cholinergic neurons, but the intracellular 
signals of these sensors and their subsequent ef-
fector products are not well understood.23-25
A paucity of enteroendocrine cells might lead 
to generalized malabsorption if it decreased in-
testinal transit time.1 Although we did not carry 
out gastric-emptying studies in our patients, the 
results of barium imaging of two of the cases sug-
gested normal luminal transit. Cholinergic neu-
rons clearly influence intestinal motility and can 
be influenced by effector products secreted by 
adjacent enteroendocrine cells.26,27 However, the 
index patient was intolerant to simple amino acid 
solutions, suggesting that rapid transit by itself 
would not be likely to lead to such profound mal-
absorption.
Our patients and Neurog3−/− mice were found 
to have normal disaccharidase activities; the mice 
have normal targeting of lactase to the brush-bor-
der membrane, suggesting that the apical target-
ing of these enzymes is not defective.6 Although 
NEUROG3 is not abundantly expressed in entero-
cytes, most genes that express proteins with im-
portant roles in nutrient assimilation are aug-
mented by a hepatocyte nuclear factor (HNF1).28 
Since HNF1 is known to form a heterodimer with 
NEUROG3, the absorptive capacity of the entero-
cyte may be deleteriously affected in the absence 
of the NEUROG3–HNF1 complex.29 The localiza-
tion and abundance of brush-border enzymes and 
transporters in humans with a deficiency of 
NEUROG3 have yet to be analyzed. Alternatively, 
the presence of progenitor or mature enteroendo-
crine cells that express NEUROG3 could be im-
portant for the normal development of the absorp-
tive cells.
The two eldest patients (Patients 2 and 3) have 
recently shown evidence of hyperglycemia that has 
yet to be thoroughly investigated. Mouse studies 
have shown that Neurog3 has a nonredundant role 
as a proendocrine master switch in the pancreas 
as well as the gut.3-6 The absence of overt glucose 
intolerance, even with intravenous glucose admin-
istration, in our patients suggests that another 
putative, unidentified factor can at least par-
tially compensate for the absence of functional 
NEUROG3 and stimulate the development of pan-
creatic islet cells. Six forms of maturity-onset dia-
betes of the young (MODY) have been identified 
and are attributable to heterozygous mutations 
of genes that critically affect the development and 
function of beta cells.30 No mutations of NEUROG3 
have been identified in patients with MODY31; 
it would be interesting to evaluate whether our 
patients and their related obligate heterozygotes 
have evidence of considerable glucose intolerance, 
since such evidence would qualify NEUROG3 as 
a candidate gene for MODY. These findings may 
also help uncover the cause of several other asso-
ciated forms of diarrhea, including diarrhea-pre-
dominant irritable bowel syndrome and various 
inflammatory and other forms of congenital di-
arrhea.32
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